U.S. Residents
Dermatofibrosarcoma Protuberans
Dermatofibrosarcoma protuberans (DFSP) is a rare, soft-tissue neoplasm of low- to intermediate malignancy. It constitutes less than 0.1% of all malignant neoplasms and less than 2% of all soft-tissue sarcomas.1,2 Although DFSP rarely metastasizes, it is highly invasive and locally aggressive.3
Epidemiology
DFSP is rare, with an estimated annual incidence of ~0.8 cases per million persons.1,3 It typically affects young to middle-aged adults (20-50 years old), and it occurs with almost equal frequency in men and women.1
Glivec® (imatinib) | Investigations of Targeted Therapy With imatinib For DFSP
Treatment Options For Dermatofribrosarcoma Protuberans (DFSP): Glivec® (imatinib)
References :
1. Gloster HM, Jr. Dermatofibrosarcoma protuberans. J Am Acad Dermatol. 1996;35:355-374; quiz 375-376.
2. Mendenhall WM, Zlotecki RA, Scarborough MT. Dermatofibrosarcoma protuberans. Cancer. 2004;101:2503-2508.
3. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Dermatofibrosarcoma. Version 2. 2005. Available at: http://www.nccn.org/professionals/physician_gls/PDF/dfsp.pdf. Accessed April 23, 2006.
